Interim Chief Executive Officer
Adam Taich is the interim Chief Executive Officer at SomaLogic. He has over 20 years of experience in the life sciences and healthcare markets. His career has spanned a diverse set of roles, including general management, operations, commercial, finance, strategy, and corporate development.
Mr. Taich joined SomaLogic in late 2021 as Chief Business Officer. In mid-2022, he was appointed to lead the Life Sciences business. Prior to joining SomaLogic, Mr. Taich served as the Vice President and General Manager of the Molecular Biology business of Thermo Fisher Scientific. In this role, he was instrumental in standing up the company’s response to supply critical raw materials for COVID-19, as well as managing a complex, global P&L with revenues in excess of $1 Billion. While at Thermo Fisher, he also led the Protein and Cell Analysis business, strategy, and corporate development for the Life Sciences Group, Global Service and Support, and a variety of finance leadership roles earlier in his career. He joined Thermo Fisher via their acquisition of Life Technologies. Earlier in his career, he was an Associate in the M&A Group at Donaldson, Lufkin, and Jenrette in New York City.
Mr. Taich received his Bachelor of Arts from Miami University in Oxford, Ohio.